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Abstract: 
 
There is growing interest in the design of synthetic molecules that mimic the structures and 
functions of epitopes found on the surface of peptides and proteins. Epitope mimetics can 
provide valuable tools to probe complex biological processes, as well as interesting leads for 
drug and vaccine discovery. One application of epitope mimetics is reviewed here, focusing 
on mimetics of the cationic antimicrobial peptides that form part of the innate immune 
response to microbial and viral infection in many organisms. Mimetics of these naturally 
occurring peptides and proteins may be useful to explore mechanisms of antimicrobial and 
immunomodulatory action, and as a potential source of new antibiotics to address one of the 
most pressing current threats to human health. 
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Introduction 
A "protein epitope mimetic" is a conformationally constrained synthetic molecule that 
mimics the three-dimensional (3D) structure of that part of a folded peptide or protein 
recognized by its cognate biological receptor. This definition is closely related to the 
traditional view of an epitope, or "antigenic determinant", as being the part of an antigen 
recognized by antibodies and T-cell receptors (TCRs). The perspective here, however, is 
broader and includes not just structures recognized by antibodies and TCRs but also epitopes 
involved in ligand-receptor, protein-protein and protein-nucleic acid interactions (PPIs and 
PNIs). Most important are the 3D structures of epitopes and their mimicry in "semi-rigid" 
molecules. Protein epitope mimetics are interesting structurally and stereochemically, but 
more importantly, as tools to interrogate biological systems and as leads in drug and vaccine 
discovery. 
 Various levels of epitope complexity can be considered, starting with epitopes formed 
by short polypeptide segments at the protein surface, including ß-turns, loops and stretches of 
helical- or ß-structure. ß-Hairpins include both a turn (or loop) and regions of regular ß-
structure. Early successes in the design of ß-turn mimetics came in the 1980's and 1990's, 
whereas over the past decade several successful approaches to helical, ß-sheet and ß-hairpin 
mimetics have been described [1-5]. More complex is the mimicry of discontinuous epitopes, 
comprising multiple polypeptide chain segments lying adjacent on the protein surface and 
adopting multiple types of secondary structure; here remains an important challenge for the 
future [6], perhaps one that can be addressed through the evolving field of "foldamer 
chemistry" [7,8]. 
 Protein epitope mimetics typically sit in a still relatively unexplored area of molecular 
space (ca. 0.5-5 kDa). Nature has evolved molecules in this size range, including many 
structurally complex polyketide and peptide-based natural products. On the other hand, an 
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alternative source of such molecules is found by taking the macromolecules and 
macromolecular assemblies of Nature as a source of inspiration for mimetic design. 
Furthermore, many synthetic protein epitope mimetics tend to be modular in structure. They 
can be constructed from building blocks, such as α- or ß-amino acids or peptoids, which can 
be linked together using robust and efficient methods. It then becomes straightforward, in 
principle, to exchange building blocks and so vary structures (and optimize properties) in a 
combinatorial fashion using parallel synthetic chemistry, something that is not so easy when 
starting from complex natural products. 
 Molecular recognition involving proteins is mediated by surface exposed secondary 
structure elements such as ß-turns, ß-strands, ß-hairpins and α-helices. Protein epitope 
mimetics, therefore, seem to be attractive starting points for the design of PPI (and PNI) 
inhibitors (Figure-1). Inhibitor design for such targets based on small drug-like molecules has 
often proven rather difficult [9]. Protein epitope mimetic design offers an alternative 
approach, which draws upon improving knowledge of the structures of PPI hot-spots and the 
mechanisms of PPIs [10]. Another area where protein epitope mimetics have great potential 
is in synthetic vaccine design. Here the epitope mimetic should indeed act as an antigenic 
determinant, not simply to mimic the structure and receptor binding properties of a specific 
target, but rather to stimulate the immune system to produce antibodies and/or cyotoxic T 
cells that recognize an invading pathogen. 
 In the remainder of this short review, the focus is on one application of protein 
epitope mimetics, for the discovery of novel anti-infective agents. 
 
Antibacterial CAMPs 
The WHO has identified antibiotic resistance as one of the greatest current threats to human 
health [11]. The reasons for this include the paucity of new antimicrobial drugs currently 
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under development and the rapid spread of drug resistant bacteria [12]. In 2009 the Infectious 
Diseases Society of America (ISDA) challenged the USA and EU to develop ten new 
licensed antibiotics within the next 10 years, called the 10x'20 initiative 
(www.idsociety.org/10x20.htm) [13,14]. In order to address this challenge, it is important to 
consider new approaches to antibiotics that complement and extend established methods, 
such as natural product discovery and modification, whole-cell screening of compound 
libraries, and in vitro screens developed using genomic, proteomic and structural data [15-
17]. One alternative approach is the design of mimetics based upon the cationic peptide and 
protein effector molecules produced by cells in the innate immune system, which provide a 
first line of defense against microbial infection in birds, fishes, amphibians, reptiles, 
mammals (including humans), insects, and other organisms [18]. 
 Cationic antimicrobial peptides (CAMPs), or so-called host-defense peptides, play 
important roles in the anti-infective defense mechanisms of many organisms, including those 
of animals that also possess a more complex adaptive immune system. They are typically 
short cationic peptides of ~10-50 residues, with a net positive charge of +2 to +10, and often 
share amphipathic properties (cationic/hydrophobic). They differ widely, however, in 
sequences and secondary structures (Figure-2) (for recent reviews see [19-21]). Nevertheless, 
their physical properties frequently allow CAMPs to bind and insert into phosholipid bilayers 
by "barrel-stave", "carpet" or "toroidal-pore" mechanisms, and so disrupt the membrane 
bilayer [19]. CAMPs typically possess broad-spectrum antimicrobial activity against Gram-
negative and Gram-positive microorganisms, but in the micromolar rather than the nanomolar 
range often seen with clinically used antibiotics. Nature has evolved CAMPs with such 
properties most likely because they are are released directly at sites of infection by effector 
cells, and then act locally in a number of ways, including by selective perturbation of 
microbial cytoplasmic membranes. In contrast, the relatively high concentrations of CAMPs 
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needed for antimicrobial activity, their ready degradation by proteases in serum, and their 
higher toxicity, are major obstacles for their development and use in the systemic treatment 
of bacterial infections in humans. 
 The mechanisms of action of CAMPs, however, have additional layers of complexity. 
Firstly, the (outer) bacterial membranes are not simple bilayers containing phospholipids. The 
membranes of Gram-positive bacteria are typically covered in a thick layer of peptidoglycan, 
teichoic acid, and protein, whereas the outer membrane (OM) of Gram-negative bacteria are 
often asymmetric, with the outer leaflet comprising mostly lipopolysaccharide (LPS) [22]. 
Individual LPS molecules in the outer leaflet are then cemented together through 
coordination of the phosphate and carboxylate groups in lipid A to divalent cations such as 
Mg2+. It seems certain that cationic molecules (such as peptides and aminoglycosides) would 
be attracted electrostatically to the OM, perhaps leading to a pre-concentration in the outer 
sheaf [23]. This pre-association with the bacterial surface has been implicated in the self-
promoted uptake of peptides across the OM, perhaps through competion with Mg2+ for 
binding to LPS in Gram-negative bacteria like E. coli and P. aeruginosa [24]. But the 
molecular details of whether/how this might occur remain unclear. Certainly, many CAMPs 
act by disrupting microbial membranes, and in these cases both enantiomers tend to show the 
same antimicrobial activity, ostensibly due to a lack of chiral discrimination within the 
interior of the cell membrane. However, it is worth noting that some aminoglycosides remain 
active in both enantiomeric forms [25] although they target a chiral molecule - the ribosome 
[26]. Secondly, it is clear that in some cases CAMPs are able to penetrate the bacterial 
membrane(s), and gain access to protein or nucleic acid targets inside the cell, as reviewed 
elsewhere [27]. Thirdly, it should be remembered that many CAMPs also have broad 
functions in the immune systems of their hosts, in addition to their antimicrobial activity 
[20,21]. They act at the interface of the innate and adaptive immune responses, and 
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participate in multiple aspects of immunity, inflammation, wound repair, and in maintaining 
homeostasis [28,29]. Recently, it was shown that some natural host-defence peptides, as well 
as synthetic analogues, can trigger a range of immunomodulatory responses, including an 
ability to moderate Toll-like receptor (TLR)-mediated responses stimulated by pathogen-
associated molecular patterns and to protect against lethal endotoxemia and infections in 
animal models [20,21,28,30,31]. Other host-defence peptides such as the defensins and LL-
37 also have immunomodulatory activities that likely mediate protection in animal models. 
The detailed molecular mechanisms of these innate immune effects, however, remain poorly 
characterized.  
 These considerations suggest that CAMPs will be interesting starting points for 
peptidomimetic and foldamer design, with the aim of probing this biology and perhaps 
discovering molecules with interesting antimicrobial and/or immunomodulatory properties. 
 
CAMP mimetics 
Antimicrobial peptides  
Many hundreds or thousands of linear synthetic peptides related to naturally occurring 
CAMPs have been reported that possess membrane lytic activity (e.g. [32-36]). However, it 
remains doubtful whether flexible linear peptides can be endowed with the properties, 
including high potency, target selectivity, low toxicity and stability in serum and in whole 
animals, required for drug development. On the other hand, these properties are easier to 
achieve with conformationally constrained peptidomimetic scaffolds. A lead can be taken 
from Nature, where many examples of backbone cyclic cationic peptide antimicrobial 
products are known [37]. For example, many analogues of natural products such as 
gramicidin S and tyrocidine have been reported, although their antimicrobial activities 
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(MICs) usually remain in the micromolar range, and like the natural products, many are also 
strongly hemolytic. 
Antimicrobial peptidomimetics 
Many synthetic peptidomimetic approaches to antimicrobial peptides have been described or 
reviewed recently [38-40], including those based on hairpin mimetics [41-44], ß-peptides 
[45-54], peptoids [55-59], oligomeric aryl amides and aryl ureas [60-63], as well as related 
oligomers [64], foldamers and polymers (Figure-3) [65-73]. 
Novel mechanisms of antimicrobial action 
Of special interest are cases where mixed and/or novel mechanisms of antimicrobial action 
can be demonstrated for CAMP-derived peptidomimetics. Already many years ago it was 
noted that individual CAMPs differ widely in their ability to depolarize the cytoplasmic 
membrane potential in Gram-positive and Gram-negative bacteria [24,74,75]. Gramicidin S, 
for example, causes maximal depolarization around the MIC, suggesting that the lytic actions 
of this peptide are directly responsible for bacterial cell death. Other CAMPs, however, such 
as polymyxin, cause little membrane depolarization at concentrations around the MIC, 
suggesting that the mechanism of cell death may involve some event other than the 
breakdown of the membrane permeability barrier. More recently, the kinetics of bacterial cell 
killing by antimicrobial arylamide foldamers was shown not to correlate with the effects of 
these molecules on bacterial membrane depolarization, suggesting again a mixed mechanism 
of action [61]. 
 An interesting family of mimetics modelled on the ß-hairpin structure of the CAMP 
protegrin I (PG-I) was shown recently to have a novel mechanism of action [44]. The 
mimetics, typified by L27-11 and POL7001, have a backbone cyclic structure constrained 
into a ß-hairpin conformation with a D-Pro-L-Pro template [1]. The discovery of L27-11 and 
POL7001 was enabled in particular by the availability of an efficient parallel synthesis 
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method, which allowed the screening of compound libraries based upon this scaffold, and 
stepwise optimization of antimicrobial activity. Although PG-1 is strongly membrane lytic 
[76], both L27-11 and POL7001 are non-lytic at micromolar concentrations, and yet have 
potent antimicrobial activity in the nanomolar range, but only against Gram-negative 
Pseudomonas sp. The activity is highly enantioselective, which strongly suggests that a 
(chiral) receptor is required for the antimicrobial activity [44]. A likely target was shown to 
be the ß-barrel OM protein LptD (also called OstA and Imp), which plays an essential role in 
the assembly of the LPS layer in the outer leaflet of the OM in many Gram-negative bacteria 
(Figure-4) [77,78]. The interaction of the peptidomimetics with P. aeruginosa LptD was 
proven by photoaffinity labelling [44], but the binding site has not yet been characterized in 
detail. LptD is known to form a complex with the lipoprotein LptE in the OM where together 
they are responsible for the transport of LPS from the periplasm into the outer leaflet of the 
OM [77,79,80]. No crystal structure of LptD (from any microorganism) is currently 
available. It is also unclear how LptD interacts with LptE and how LPS transport to the outer 
leaflet occurs. The results available so far support the hypothesis that the antimicrobial 
activity of the ß-hairpin mimetics is due to inhibition of the key transport function of LptD, 
which then blocks OM biogenesis. More detailed studies are now required to investigate the 
influence the mimetics have on LPS transport to the OM. 
Other CAMPs that target OM proteins  
Some naturally occurring antimicrobial peptides and proteins are known to interact with ß-
barrel OM proteins in Gram-negative bacteria, in particular, the colicins and closely related 
bacteriocins and microcins [81]. Many of these peptides and proteins have been shown to 
hijack ß-barrel proteins, including porins (OmpA/C/F) and those used to transport vitamin 
B12 and iron across the OM, to gain access to the periplasm. Recently, an intrinsically 
unstructured region close to the N-terminus of bacteriocin ColE9a was observed in a crystal 
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structure inside the OmpF ß-barrel.[82] The killing mechanisms of these antibiotics, 
however, are unrelated to the mechanism of transport across the OM, and typically involve 
protein or nucleic acid targets in the cytoplasm [81]. On the other hand, no natural products 
(including peptides or proteins) have so far been reported that interact with LptD or related 
essential OM proteins, such as BamA/Omp85/YaeT [83]. This is all the more surprising 
given their essential functions in OM biogenesis, and their exposed position in the OM. 
Peptidomimetics targeting CXCR4 
Polyphemusin is a naturally occurring ß-hairpin CAMP (Figure-2) with antiviral activity 
against HIV-1 due to its ability to antagonize the chemokine receptor CXCR4; the major co-
receptor used by T-cell-tropic (X4-) HIV-1 to invade T-lymphocytes. CXCR4 is a G-protein 
coupled receptor that binds a protein ligand called "stromal cell-derived factor-1" (SDF-1 or 
CXCL12). Polyphemusin has been used as a starting point for the discovery of potentially 
useful CXCR4 antagonists [84-88]. One example is a family of backbone cyclic ß-hairpin 
mimetics, which again exploit the D-Pro-L-Pro template and a disulfide cross-link to stabilize 
hairpin conformations. Recently, an X-ray crystal structure revealed how one hairpin peptide 
binds to an engineered form of CXCR4 (Figure-4) [89]. The ß-hairpin inserts deep into the 
SDF-1 binding pocket, where a network of polar, hydrogen-bonding and hydrophobic 
contacts between the ligand and the receptor are responsible for the specific high affinity 
interaction. The ligand-binding site on CXCR4 is formed by residues in the inward-facing, 
protruding walls of the seven transmembrane helical bundle, several extracellular loops, and 
the N-terminal segment. It will be interesting to discover whether other GPCRs, that also 
have protein ligands, possess binding sites with similar architecture. If so, the structures and 
properties of the ß-hairpin scaffold might be readily optimized for interacting with such sites. 
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Figure-1. The starting points for protein epitope mimetic design are the products of structural 
and molecular biology (for example, left, the CD4-gp120-mAb crystal structure (PDB 
2QAD); right, the human papillomavirus-like particle L1 capsid (PDB 1DZL)). Some 
potential areas of application of protein epitope mimetics are highlighted. 
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Figure-2. Cationic antimicrobial peptides come in a variety of shapes and sizes. A selection 
of structures is shown, with the name and PDB file. 
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Figure-3. A selection of CAMP mimetics based on; A, oligomers and related; B, peptoids; C, 
ß-peptides. 
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Figure-4. ß-Hairpin mimetics derived from protegrin I and polyphemusin (Figure-2) bind, 
respectively, to the bacterial outer membrane protein LptD [44] and the chemokine receptor 
CXCR4 [84]; left, LptD (red) is an OM protein, comprising a C-terminal ß-barrel (the ß-
barrel shown is from PDB 2VQI) and an N-terminal periplasmic domain. LptD forms a 
complex with the lipoprotein LptE (green) [77,79,80]. The structure for LptE shown is that in 
PDB 2JXP (see text); right, the crystal structure of a ß-hairpin peptide (green with red 
surface) bound to the G-protein coupled receptor CXCR4 (PDB 3oe0) [89]. A slice through 
the complex is shown in a blue surface representation, with the full ribbon structure of 
CXCR4 in white. The image was made using the UCSF program Chimera [90]. 
 
 
